Tyco Divestiture Gives Stryker Opportunity To Tie OP-1 With Ray Spinal Cage
This article was originally published in The Gray Sheet
Executive Summary
Access to Surgical Dynamics' Ray TFC and TFC Unite threaded fusion cages will allow Stryker to compete more effectively with Medtronic in the spinal fusion market, pending FDA approval of bone growth factor products
You may also be interested in...
Tyco downsizing
Diversified firm's plan to exit over 50 unidentified business units generating $2.1 bil. in sales - including at least some parts of Tyco Healthcare - will save an estimated $230 mil. by 2005, firm predicts. The restructuring program includes consolidating 219 non-healthcare facilities and cutting 7,200 employees, resulting in fiscal 2004 charges of approximately $400 mil. Fiscal fourth quarter 2003 (ended Sept. 30) results announced Nov. 4 included roughly flat revenues of $9.5 bil. and healthcare sales of $2.2 bil. (up 4.6%). The firm foreshadowed the paring of non-core businesses with the divestiture of its Surgical Dynamics spinal unit in June 2002 (1"The Gray Sheet" June 10, 2002, p. 3)...
Tyco downsizing
Diversified firm's plan to exit over 50 unidentified business units generating $2.1 bil. in sales - including at least some parts of Tyco Healthcare - will save an estimated $230 mil. by 2005, firm predicts. The restructuring program includes consolidating 219 non-healthcare facilities and cutting 7,200 employees, resulting in fiscal 2004 charges of approximately $400 mil. Fiscal fourth quarter 2003 (ended Sept. 30) results announced Nov. 4 included roughly flat revenues of $9.5 bil. and healthcare sales of $2.2 bil. (up 4.6%). The firm foreshadowed the paring of non-core businesses with the divestiture of its Surgical Dynamics spinal unit in June 2002 (1"The Gray Sheet" June 10, 2002, p. 3)...
Stryker Spine Looks To Correct Domestic Posture With Scannell Appointment
The new head of Stryker's spine business will face the challenge of accelerating U.S. sales growth for the segment with minimal assistance from the firm's OP-1 bone morphogenic protein